banner
IKK/IκB inhibitor BMS-345541, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ762

IKK/IκB inhibitor BMS-345541, Purity ≥98%

Synonym: 445430-58-0; BMS-345541; BMS-345541 free base; BMS345541; N1-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; IKK Inhibitor III, BMS-345541; IKK Inhibitor III; IKK/IκB inhibitor

  • CAS Number: 445430-58-0
  • Compound CID: 9813758
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
BMS-345541, soluble in DMSO and insoluble in ethanol and water, modulates IKK-IκB signaling pathway, which plays a key role in inflammation and immune responses. It targets IKK1 and IKK2.
Molecular Weight
255.32
Molecular Formula
C14H17N5
Targets
IKK1: 4 μM; IKK2: 0.3 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 8 mg/mL (31.32 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
BMS-345541 can be explored as a selective IκB kinase inhibitor to understand its role in modulating NF-κB signaling in inflammatory and autoimmune disease research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0